pd 153035 has been researched along with leptin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Beales, IL; Ogunwobi, OO | 1 |
Carvalheira, JB; Cintra, DE; de Souza, CT; Franchini, KG; MourĂ£o, RH; Pauli, JR; Prada, PO; Rittner, R; Rocco, SA; Ropelle, ER; Saad, MJ; Schenka, A; Vassallo, J; Velloso, LA | 1 |
2 other study(ies) available for pd 153035 and leptin
Article | Year |
---|---|
Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor.
Topics: Adenocarcinoma; Amphiregulin; Autoantibodies; Cell Line, Tumor; Cell Proliferation; EGF Family of Proteins; ErbB Receptors; Esophageal Neoplasms; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Matrix Metalloproteinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transcriptional Activation; Transforming Growth Factor alpha; Tyrphostins | 2008 |
EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Glucose; Dietary Fats; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Hypoglycemic Agents; Immunoblotting; Immunoprecipitation; Inflammation; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Interleukin-6; JNK Mitogen-Activated Protein Kinases; Leptin; Liver; Macrophages; Male; Mice; Muscle, Skeletal; NF-kappa B p50 Subunit; Nitric Oxide Synthase Type II; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2009 |